摘要
abaloparatide是一种甲状旁腺激素相关蛋白(PTHrP)类似物,通过促骨合成代谢效应提高具有骨折高风险的绝经后骨质疏松(PMOP)患者的骨密度。临床研究表明,abaloparatide在增加骨密度、降低椎体骨折和非椎体骨折发生风险方面疗效确切。其不良反应发生率与特立帕肽相近,但高钙血症发生率较低,且具有成本效果优势。
As the analogue of parathyroid hormone-related protein(PTHrP),abaloparatide promote bone anabolic effects in osteoblasts.It can effectively increase the bone mineral density in the postmenopausal osteoporosis(PMOP)patients with high risk of fractures.Clinical studies have shown that abaloparatide is effective in increasing bone density and reducing the risk of vertebral and non-vertebral factures.The incidence of adverse reactions of abaloparatide is similar to that of teriparatide,but the incidence of hypercalcemia is low,and has a cost-effectiveness advantage.
作者
张厚莉
孟伟
陈文文
张许
高洁
刘燕琳
党和勤
ZHANG Hou-li;MENG Wei;CHEN Wen-wen;ZHANG Xu;GAO Jie;LIU Yan-lin;DANG He-qin(Department of Pharmacy,the Second Affiliated Hospital of Shandong First Medical University,Taian SHANDONG 271000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2023年第2期114-118,共5页
Chinese Journal of New Drugs and Clinical Remedies
基金
吴阶平医学基金会临床科研专项资助基金(320.6750.2020-17-1)
山东省医药卫生科技发展计划(2018WS120)
泰安市科技创新发展项目(2020NS226)
山东第一医科大学潜力提升计划(2019QL017)。
